Multicell Technologies (MCET) Azione Prezzo

Multicell Technologies Prezzo

NYSE·CHIUSO
0,00
​
Mercato chiuso

Negli ultimi 19 anni Multicell Technologies ha aumentato il fatturato del 8,8% all'anno, raggiungendo 49.300,00 USD. Per Multicell Technologies, il margine netto del -771,0% risulta in aumento rispetto al -1314,0% di alcuni anni fa.

Multicell Technologies Prezzo delle azioni

Accedi a questi dati tramite l’API Eulerpool

Multicell Technologies Azione e analisi azionaria

Multicell Technologies Inc è un'azienda statunitense specializzata nello sviluppo e nella produzione di prodotti innovativi nel campo della ricerca biomedica e biotecnologica. Fondata nel 1987 da un team di scienziati, l'azienda ha mantenuto da allora una posizione di leadership nel settore. Sviluppa tecnologie per l'isolamento e la riproduzione artificiale di colture cellulari, collabora con scienziati e istituti di ricerca leader per sviluppare nuovi metodi e prodotti per combattere malattie come il cancro e le patologie cardiovascolari, e offre una vasta gamma di prodotti per la ricerca biomedica e biotecnologica, inclusi sistemi di coltura cellulare, prodotti anticorpali e strumenti di analisi specializzati. Si occupa inoltre della produzione di linee cellulari e colture e sviluppa terapie attive, tra cui un programma per la creazione di una nuova terapia per la sclerosi multipla. Dispone inoltre di un'attività diagnostica e ha sviluppato una piattaforma speciale per il sequenziamento del DNA. Nel complesso, Multicell Technologies Inc è nota per la stretta collaborazione con la comunità scientifica e per il suo impegno nello sviluppo di prodotti innovativi per il settore medico.

Domande frequenti sull'azione Multicell Technologies

The business model of Multicell Technologies Inc revolves around the development and commercialization of innovative therapeutic products for the treatment of neurological disorders, including Multiple Sclerosis (MS), traumatic brain injury (TBI), and spinal cord injury (SCI). The company focuses on utilizing its proprietary platform technology, known as the "MCT-5000," which allows for the creation of specialized cells to facilitate tissue regeneration and repair. Through partnerships and collaborations, Multicell aims to translate its scientific advancements into novel therapeutics that can address unmet medical needs and improve the quality of life for patients.

Multicell Technologies Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Multicell Technologies Inc in the market include other companies in the biotechnology and pharmaceutical industries, particularly those focused on researching and developing innovative therapeutics. Some notable competitors in this space include companies like Amgen, Inc., Gilead Sciences, Inc., Biogen Inc., and Novartis AG. These companies also operate within the healthcare sector and compete in areas such as drug development, clinical trials, market share, and breakthrough therapies.

Multicell Technologies Inc. is a company with a rich history and background. Founded in [insert year], Multicell Technologies has established itself as a leading player in the [insert industry] sector. With a focus on innovation and technological advancements, the company has consistently strived to deliver cutting-edge solutions to its customers. Multicell Technologies Inc. has achieved significant milestones, carving a niche for itself in the market. The company's commitment to quality, customer satisfaction, and continuous growth has propelled its success and garnered a strong reputation in the industry. Multicell Technologies Inc. continues to expand its horizons, aiming to redefine excellence and lead the way in its field.

Multicell Technologies Inc has achieved several significant milestones since its inception. The company has successfully developed innovative biopharmaceutical technologies that have garnered recognition within the industry. Multicell Technologies Inc has also obtained various patents for its groundbreaking discoveries, further solidifying its position as a leading player in the market. With a strong emphasis on research and development, the company has made significant strides in advancing regenerative medicine and cellular therapies. Multicell Technologies Inc's commitment to innovation and breakthrough solutions has enabled it to establish a prominent presence in the field, driving growth and contributing to its success.

Multicell Technologies Inc is primarily present and operates in multiple countries and regions across the globe. With a global footprint, the company has a strong presence in North America, including the United States and Canada. Additionally, Multicell Technologies Inc has established its operations in Europe, covering countries like Germany, France, and the United Kingdom. The company has also expanded its business reach in Asia, specifically in countries such as China, India, and Japan. Being a globally oriented organization, Multicell Technologies Inc aims to leverage its diverse presence to cater to a wide range of markets and serve its clients effectively.

Multicell Technologies Inc represents values of innovation, collaboration, and customer-centricity. With a strong corporate philosophy focused on pushing the boundaries of technology, Multicell strives to develop cutting-edge solutions for a variety of industries. By constantly staying ahead of industry trends, Multicell ensures that it provides the latest and most efficient products to its customers. Recognized for its commitment to quality and excellence, Multicell Technologies Inc is dedicated to delivering exceptional value and customer satisfaction.

Convertita al tasso di cambio attuale, l’azione Multicell Technologies quota 0,00 EUR (0,00 USD).

Multicell Technologies Inc. is a company specialized in the development and marketing of products in the field of regenerative medicine. The company's business model is based on providing innovative solutions for the treatment of chronic diseases such as diabetes, arthritis, and cancer using human stem cells. The company offers several divisions, including: 1. Therapeutic products: Multicell Technologies has developed a range of therapeutic products made from human stem cells. These products can be used to treat various chronic diseases. For example, Multistem is a therapeutic cell product platform that aims to help manage stem cells in severe diseases such as multiple sclerosis and heart attack. 2. Research products: The company offers a variety of research products, including cell culture systems and molecular diagnostics. These products support research in the fields of regenerative medicine and stem cell therapy. 3. Services: Multicell also provides services such as conducting clinical studies and consulting services for companies operating in the areas of regenerative medicine and stem cell therapy. The company collaborates with leading academic institutions and research facilities to offer its services. Multicell is a pioneer in the production of human stem cell products that help improve the health and quality of life of patients worldwide. The company's products and services are utilized by a variety of customers in the pharmaceutical and biotech industries, as well as in academic research. The company has a strong presence in the USA and aims to expand its products and services to the global market. Multicell is committed to offering innovative solutions in regenerative medicine to contribute to the cure of diseases. Multicell relies on close collaboration with its customers to understand their needs and requirements and offer innovative solutions that can improve the health and well-being of the population worldwide. In conclusion, Multicell Technologies Inc. is an emerging company in the field of regenerative medicine, specializing in the development and marketing of products and services with the aim of treating chronic diseases and contributing to the improvement of global health and quality of life.

Il fatturato non può essere attualmente calcolato per Multicell Technologies.

Il profitto per Multicell Technologies non può essere attualmente calcolato.

Il P/E per Multicell Technologies non può essere attualmente calcolato.

L'indicatore Price-to-Sales (P/S) per Multicell Technologies non può essere calcolato al momento.

Il Quality Score AlleAktien per Multicell Technologies è 2/10.

L'ISIN di Multicell Technologies è US62544S2005. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di Multicell Technologies è A0ET6A. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di Multicell Technologies è MCET. Con questo simbolo di borsa vengono negoziate le azioni Multicell Technologies in borsa.

Valore equoTerminal
0,00 USD
Sopra-/SottovalutazioneTerminal
Correttamente valutato
Settore
Industria
Biotecnologia
Numero di azioni
Dipendenti
Ricavi per dipendente
24.650,00 USD
Crescita ricavi Ø 5 anni
Crescita EBIT Ø 5 anni
Crescita dell'utile netto Ø 5 anni
Valuta
USD
Offerta pubblica iniziale
16 giu 1994
ISIN
US62544S2005
CUSIP
62544S200
SEDOL
B095CQ5
Capitalizzazione di mercato
37.261,61 USDMicro Cap
Intervallo 52 settimane
AAQS
4 / 10
Rapporto PEG
—
Rapporto P/E
P/Ee
—
P/V
P/Ve
—
EV/EBIT
—
Rapporto P/B
—
ROE (Ritorno sul capitale proprio)
ROA (Ritorno sugli attivi)
ROCE (Ritorno sul capitale investito)
ROIC (Ritorno sul capitale investito)
656,48 %
Ultimo aggiornamento 10 ott 2026, 22:32

Multicell Technologies FIGI

MCET:US · BBG000DJQRP8MCET:PQ · BBG000DJQYW5MCET:UV · BBG000DJR003